- Conditions
- Sneddon-Wilkinson, Acrodermatitis Continua of Hallopeau, Pustular Psoriasis, Palmoplantar Pustulosis
- Interventions
- Anakinra
- Drug
- Lead sponsor
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
- NIH
- Eligibility
- 18 Years to 110 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–12
of 12
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Miami, Florida • Tampa, Florida + 1 more
- Conditions
- Psoriasis
- Interventions
- Placebo for Risankizumab, Risankizumab
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 174 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 34
- States / cities
- Glendale, Arizona • Hot Springs, Arkansas • Rogers, Arkansas + 30 more
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Spesolimab
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 2
- States / cities
- Irvine, California • Fargo, North Dakota
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Spesolimab
- Drug
- Lead sponsor
- LEO Pharma
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 2
- States / cities
- Auburn Hills, Michigan • New York, New York
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Imsidolimab
- Biological
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Encino, California • Largo, Florida • Miami, Florida + 2 more
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Spesolimab, Placebo
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 12 Years to 75 Years
- Enrollment
- 123 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 2
- States / cities
- Auburn Hills, Michigan • St Louis, Missouri
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab, Standard of Care (SOC), Imsidolimab 750 mg IV/200 mg SC
- Drug · Other
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 5
- States / cities
- Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more
- Conditions
- Palmo-plantar Psoriasis
- Interventions
- Apremilast, Placebo
- Drug
- Lead sponsor
- Innovaderm Research Inc.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Arlington Heights, Illinois
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo
- Drug · Other
- Lead sponsor
- Vanda Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 5
- States / cities
- Largo, Florida • Louisville, Kentucky • Ann Arbor, Michigan + 2 more
- Conditions
- Generalized Pustular Psoriasis
- Interventions
- Not listed
- Lead sponsor
- CorEvitas
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2099
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Palmoplantar Psoriasis, Genital Psoriasis
- Interventions
- Deucravacitinib, Placebo
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 20
- States / cities
- Phoenix, Arizona • Fountain Valley, California • Los Angeles, California + 15 more